---
layout: default
title: Aluminum Oxide Calcium Silicate Magnesium Sulfate 
parent: 僅模型預測 (L5)
nav_order: 301
evidence_level: L5
indication_count: 0
---

# Aluminum Oxide Calcium Silicate Magnesium Sulfate 
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Mineral Compound (Al₂O₃ / CaSiO₃ / MgSO₄ / SiO₂ / S / Ti / Zn): Preliminary Assessment — Insufficient Data for Repurposing Analysis

## One-Sentence Summary

This entry represents a multi-component inorganic mineral mixture (aluminum oxide, calcium silicate, magnesium sulfate heptahydrate, silicon dioxide, sulfur, titanium, and zinc), with no registered indication in the United States and no DrugBank ID on record.
The TxGNN model returned **no predicted indications** for this compound, and the pipeline found **0 clinical trials** and **0 publications** directly associated with this mixture as a unified pharmaceutical entity.
The evidence base is currently insufficient to support a repurposing hypothesis.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Unknown — no US license on record |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only; no predictions generated) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

This query submitted a seven-component inorganic mixture as a single drug entity. TxGNN's knowledge graph is built around single molecular entities mapped to DrugBank IDs. Because:

1. No DrugBank ID could be resolved for this combination,
2. The mixture lacks a unified INN (International Nonproprietary Name), and
3. The individual components (aluminum oxide, titanium, silicon dioxide, etc.) are primarily classified as excipients, cosmetic ingredients, or mineral supplement constituents rather than pharmacologically active small molecules,

the model had no anchor node in the knowledge graph and therefore generated zero repurposing candidates.

Each component may individually carry known biological activities — zinc has wound-healing and anti-inflammatory properties, sulfur is a keratolytic agent, and magnesium sulfate has osmotic and neuromuscular effects — but as a combined unnamed entity, they cannot be evaluated by the current pipeline without further decomposition or reformulation of the query.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This submission does not correspond to a single pharmacological entity recognizable by TxGNN or any US regulatory database. No predictions, safety data, or clinical evidence could be retrieved, making a repurposing assessment impossible at this stage.

**To proceed, the following is needed:**

- **Clarify the drug entity**: Determine whether this is a fixed-dose combination product with a known brand name, an excipient blend, or a cosmetic formulation — and resubmit using the individual active ingredient(s) of interest.
- **Resolve DrugBank identity**: Each component should be queried separately in DrugBank to retrieve MOA, pharmacology, and known indications.
- **Confirm regulatory scope**: If the intended active component is zinc or sulfur (the most pharmacologically active ingredients here), re-run the pipeline using those individual INNs.
- **MOA data collection**: Once individual active ingredients are identified, retrieve mechanism-of-action data from DrugBank or ChEMBL to enable knowledge graph traversal.
- **Safety baseline**: Obtain package insert or safety sheet for any candidate active ingredient before proceeding to S1 safety screening.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

